Remove Blogging Remove Pricing Remove Thousand Oaks
article thumbnail

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Xconomy

Just as many M&A rumors flame out as lead to deals, of course, but the news was enough to give Biogen’s stock price a big bump, and ignite chatter about what a sale of one of biotech’s heavyweights would mean, particularly for the Boston area. The rumors boosted Biogen’s sinking stock price nearly 10 percent.

article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

BIO president and CEO Jim Greenwood (pictured), a former Congressman-turned-lobbyist, told an audience, “We are fighting back,” and unveiled plans to put some of the blame for high drug prices on insurance companies. The new prices don’t reflect rebates and discounts.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.